BTAX OTC

Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.